Krishna Institute of Medical Sciences Limited has successfully concluded its board meeting held on March 11, 2026, with the approval of a significant fund raising proposal worth ₹1,500 crores. The company had earlier informed stock exchanges about the meeting scheduled to deliberate on fund raising options, filing the intimation on March 6, 2026, in compliance with SEBI LODR Regulations.

Board Meeting Outcomes

The board meeting, convened under Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, has resulted in concrete decisions regarding the company's capital raising strategy. The meeting commenced at 12:00 Noon and concluded at 1:20 PM, with the board approving the issuance of equity shares through Qualified Institutions Placement (QIP) as the preferred methodology.

Fund Raising Methodology

The company has finalized its approach to raise funds for an aggregate amount of up to ₹1,500 crores through equity share issuance via QIP mechanism and/or any other permissible mode or combination thereof. The issuance will be conducted in one or more tranches, in accordance with the applicable provisions of the Companies Act, 2013 and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Postal Ballot Approval

In addition to approving the fund raising proposal, the board has also approved the conduct of a postal ballot to seek shareholders' consent for the proposed equity issuance. The board has approved the Postal Ballot Notice, which will be circulated to members in due course, in accordance with applicable laws. This step ensures proper governance and member participation in the capital raising decision.

Committee Authorization

The board has authorized the Finance & Investment Committee to decide the terms and conditions of the proposed fund raise. The final terms and conditions of the QIP will be determined based on market conditions and regulatory requirements at the time of issuance, subject to receipt of necessary approvals including shareholders' approval and other regulatory and statutory approvals as may be required.

Krishna Institute of Medical Sciences Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, demonstrating strong operational performance and strategic expansion initiatives. The healthcare services provider has also completed regulatory compliance requirements by filing necessary documentation with stock exchanges regarding newspaper publication of its financial results.

Consolidated Financial Performance

The company delivered robust consolidated financial results for Q3FY26, with revenue from operations showing substantial growth compared to the previous year.

For the nine-month period ended December 31, 2025, the company maintained strong momentum with consolidated revenue from operations reaching Rs 28,300 million compared to Rs 22,381 million in the corresponding period of the previous year, marking a growth of 26.43%.

Standalone Results Show Consistent Growth

The standalone financial performance also reflected positive trends, with the parent company showing healthy operational metrics.

The standalone revenue growth of 27.17% in Q3FY26 demonstrates the core business strength, while the nine-month standalone revenue reached Rs 12,453 million compared to Rs 10,382 million in the previous year.

Strategic Investment in Material Subsidiary

The Board of Directors approved a significant strategic initiative involving increased investment in Sarvejana Healthcare Private Limited, the company's material subsidiary operating Sunshine Hospital.

Sunshine Hospital, incorporated on December 3, 2008, operates as a specialized orthopedic hospital with joint replacement as its core service, supplemented by other high-end healthcare facilities including cardiology and transplant services.

Regulatory Compliance and Publication

The company has fulfilled its regulatory obligations under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results were published on February 6, 2026, in Financial Express (English) and Navatelangana (Telugu) newspapers. Company Secretary Nagajayanthi J.R. filed the compliance documentation with BSE and NSE on February 7, 2026, confirming adherence to disclosure requirements. The published results are also accessible on the company's website under investor disclosures section.